- Extreme volatility: 2.84% daily swings are normal (StockInvest Data)
- Regulatory hurdles: FDA scrutiny can halt progress instantly
- Cash burn: Negative $87M free cash flow requires continuous financing
- Clinical trial failures: Any pipeline setback could crash the stock 30-50%
- Competition: Big pharma giants with deeper pockets
How to Buy TG Therapeutics, Inc. (TGTX) Shares - Investment in TG Therapeutics, Inc. (TGTX) Stock
Updated on 20 Aug 2025
Thinking about investing in a biotech company that's making waves in multiple sclerosis treatment? TG Therapeutics, Inc. (TGTX) offers exciting growth potential with its flagship drug BRIUMVI showing explosive revenue growth. This could be your chance to get in on a medical breakthrough story while building your investment portfolio.
Article navigation
- 📈 TG Therapeutics Stock: Current Price and Critical Dates
- 📊 6-Month Price Journey (February-August 2025)
- 🔮 Price Forecast: 2025-2030 Outlook
- ⚠️ Key Risks vs. Positive Signals
- 🛡️ What Should a Beginner Trader Do Today?
- ✅ How to Buy TG Therapeutics, Inc. (TGTX) Shares – Step by Step
- 💡 Why Pocket Option Fits New Investors
- 🌍 TG Therapeutics in 2025: MS Treatment Innovator
📈 TG Therapeutics Stock: Current Price and Critical Dates
As of August 20, 2025, TG Therapeutics, Inc. (TGTX) trades at $28.08 on NASDAQ. Mark your calendar: November 3-5, 2025 is absolutely critical – that’s when the company reports Q3 earnings. Historically, these reports create massive price movements.
How Earnings Reports Move TGTX Stock
| Date | Event | Pre-News Price | Post-News Change |
|---|---|---|---|
| Aug 4, 2025 | Q2 Earnings | $34.20 | -18% (earnings miss) |
| May 5, 2025 | Q1 Earnings | $32.80 | +8.5% (revenue beat) |
| Feb 10, 2025 | Annual Results | $29.50 | +12% (guidance raise) |
| Nov 4, 2024 | Q3 Earnings | $27.80 | +15% (BRIUMVI growth) |
| Aug 5, 2024 | Q2 Earnings | $25.10 | +22% (market expansion) |
| May 6, 2024 | Q1 Earnings | $22.40 | +18% (FDA updates) |
Trend Insight: TGTX shows extreme sensitivity to earnings reports, with swings averaging ±15%. Positive surprises create explosive gains, while misses cause sharp declines. The recent -18% drop after Q2 shows how volatile this biotech stock can be.
📊 6-Month Price Journey (February-August 2025)
TG Therapeutics shares experienced a rollercoaster ride, declining 19.2% overall but showing incredible volatility:
February: $34.70 (post-annual report high)
March: $38.90 (BRIUMVI sales momentum)
April: $36.20 (profit-taking phase)
May: $35.60 (Q1 earnings digestion)
June: $32.80 (market uncertainty)
July: $29.40 (sector-wide biotech selloff)
August: $28.08 (post-Q2 earnings decline)
Why the volatility? Biotech stocks live and die by clinical data and quarterly results. TGTX’s 91% revenue growth couldn’t overcome the earnings per share miss in Q2, showing how perfection is expected in this sector.
🔮 Price Forecast: 2025-2030 Outlook
2025 (Year-End): $32-38
Based on raised BRIUMVI guidance of $570-575 million and potential Q3 recovery → BUY on dips
2026: $45-52
Expected market expansion into new territories and potential subcutaneous formulation approval
2028: $60-75
Pipeline maturation and possible new indications for BRIUMVI beyond multiple sclerosis
2030: $85-110
Market leadership position in B-cell therapies and potential acquisition target for big pharma
Verdict: Strong long-term hold potential despite short-term volatility. Accumulate during weakness.
⚠️ Key Risks vs. Positive Signals
Risks to Consider
Green Lights for 2025
- Explosive growth: 91% YoY BRIUMVI revenue increase (Q2 Report)
- Raised guidance: $570-575M target shows management confidence
- Market expansion: EU, UK, Switzerland approvals secured
- Real-world success: 90% patient tolerance rates in recent surveys
- Pipeline progress: Subcutaneous formulation in development
🛡️ What Should a Beginner Trader Do Today?
- Start small – Allocate no more than 3-5% of your portfolio to high-volatility biotech
- Dollar-cost average – Buy in $100-200 increments over several months
- Set tight stop-losses – 15-20% maximum drawdown tolerance
- Monitor November earnings – This could be the make-or-break moment
Humorous take: “Trading TGTX is like dating a brilliant scientist – incredibly exciting when experiments work, but be prepared for occasional explosions in the lab!”
✅ How to Buy TG Therapeutics, Inc. (TGTX) Shares – Step by Step
| Step | Action | Why It Matters |
|---|---|---|
| 1 | Choose a trading platform | Ensure it offers NASDAQ stocks and fractional shares |
| 2 | Complete account verification | Typically takes 1-2 business days |
| 3 | Deposit funds | Start with an amount you’re comfortable risking |
| 4 | Search “TGTX” | Use the ticker symbol, not the company name |
| 5 | Select order type | Use limit orders to control entry price |
| 6 | Review and confirm | Check commission fees before finalizing |
| 7 | Monitor your position | Set price alerts for important levels |
💡 Why Pocket Option Fits New Investors
For those starting their investment journey, Pocket Option offers exceptional accessibility:
- Minimum deposit just $5 – Perfect for testing strategies with real money but minimal risk
- Lightning-fast verification – Single document upload gets you trading in minutes
- Diverse withdrawal options – Over 100 methods including cryptocurrencies and e-wallets
- Fractional shares available – Buy pieces of expensive stocks like TGTX without breaking the bank
The platform’s user-friendly interface makes navigating biotech volatility much less intimidating for newcomers.
🌍 TG Therapeutics in 2025: MS Treatment Innovator
TG Therapeutics dominates the B-cell therapy space for multiple sclerosis with BRIUMVI, capturing significant market share from established competitors. The company’s innovative approach to CD20-directed treatments has revolutionized patient care with improved tolerance and efficacy profiles.
Current market position: $4.1 billion market cap with trailing revenue of $454 million showing 86.96% gross margins – exceptional efficiency for a growth-stage biotech.
Interesting Fact: In 2025, TG Therapeutics’ research team discovered that 90% of BRIUMVI patients use acetaminophen pre-medication, which unexpectedly improved tolerance rates beyond clinical trial results – turning routine pain relief into a competitive advantage!
FAQ
Is TG Therapeutics profitable yet?
Yes! The company achieved net income of $28.2 million in Q2 2025, marking a significant turnaround from previous years.
What makes BRIUMVI different from other MS treatments?
BRIUMVI offers shorter infusion times (1-hour vs. 2-4 hours for competitors) and improved tolerance profiles based on real-world data.
How often does TGTX stock pay dividends?
The company doesn't currently pay dividends as it reinvests all profits into research and expansion.
What's the biggest risk for TG Therapeutics investors?
Clinical trial failures for pipeline products or regulatory setbacks could cause severe price declines given the stock's volatility.
Should I buy TGTX before or after earnings?
Historically, buying after earnings dips has been profitable, but this strategy requires strong risk tolerance due to the stock's extreme volatility.
Signals
Sign up for more like this
Customize your newsfeed with content you're actually interested in — get up-to-date personalized newsletter in your inbox.
Your comment
Comments are pre-moderated to ensure they comply with our blog guidelines.